A living mapping of ongoing research on interventions to prevent and treat Covid-19 Cochrane France MiRoR

We have created diagrams that describe the network of studies evaluating pharmacologic treatments. You can explore different treatment comparisons by selecting the treatment of interest in 3 different graphs: covid-nma.com/networks/

This mapping, based on textual data mining of the metadata of these trials, shows all the avenues explored by current and past clinical trials, the combinations of treatments, their main categories and the expected or observed results: covid-nma.com/treatment_mapp…

Please take the time to read the following thread and please retweet as it deserves coverage. It is about Artemisia and two very "interesting" (or should I say problematic) studies.

Bonjour Conforama, j'ai commandé une armoire et je ne reçois aucune nouvelle pour la livraison. Le magasin n'est pas joignable. MP n'est pas répondue.

Here is the representation of our new evidence ecosystem for #COVID19 published in Annals of Int Med : acpjournals.org/doi/10.7326/M2…

We provide a living mapping of ongoing RCTs evaluating the effectiveness of interventions for preventing and treating COVID-19: the 1834 studies identified are listed here: covid-nma.com/dataviz/. Scroll down to see the full list. This is updated weekly

Get the most from our interactive map! You can use filters to search trials by registration date, recruitment status and country. Then click on the ID of the study of interest to access its registry page. Try here: covid-nma.com/dataviz/

We provide a living mapping of trials on vaccines for COVID-19, that is updated weekly. The 90 studies identified are listed here: covid-nma.com/vaccines/mappi…. Scroll down to see the full list!

Lockdown vs Economic Growth? No, control the virus and your economy does better. Here’s the data, from Financial Times

Our #OpenAccess paper aims to visualize the state of research response to #COVID19 to inform decision-makers in research planning COVID-NMA Romain Vuillemot Pierre Ripoll @[email protected] @BOUTRON1

COVID-END is a partnership of more than 50 of the largest evidence-synthesis, technology-assessment and guideline groups supporting decision-making about #COVID19 globally. See our list of partners ow.ly/XbpJ50C05ad

New paper out with Ioana A Cristea and John Ioannidis in Epidemiology & Psychiatric Sciences : Preserving equipoise and performing randomized trials for COVID-19 social distancing interventions cup.org/2TvI6r3

👇 please share with PhD students in the life sciences to participate in this survey on difficulties making important decisions while conducting research, analysing data, writing manuscripts and responding to peer reviewers.

Monitoring transparency across all 2.75 million open access articles on #PubMedCentral reveals that disciplines, journals & publishers abide by principles of transparency to varying degrees over time Stelios Serghiou &co METRICStanford #PLOSBiology plos.io/3qeobLq

States vaccinating Exceptionally more white people than their share of the population: New York, New Jersey, Minnesota, Massachusetts, Connecticut, Delaware, Colorado, Arizona. A number of those states talk a good game on equity. And yet...

My new piece is out Vaccinating US children, who have astonishingly low chances of MIS-C & death, BEFORE you vaccinate 70 and 80 year olds all around the world is a ludicrous and unethical idea 👇👇 medpagetoday.com/infectiousdise…

"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials" New from METRICS, including Cathrine Axfors and Lars G. Hemkens and more! nature.com/articles/s4146…